Heartflow, Inc. Common Stock (HTFL) - Stock Analysis
Last updated: Jun 22, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
HeartFlow (HTFL) has multiple fresh growth catalysts—Aetna coverage expansion Jan 6, 2026, new clinical data at ACC and the launch/enrollment of the 5,000‑patient NAVIGATE‑PCI registry on March 16, 2026—and its stock has surged ~20–30% off the March low, positioning it as a high‑beta, event-driven healthcare IT momentum trade despite ongoing operating losses.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: • Strong liquidity • Persistent losses • Weak cash flow HTFL has a strong liquidity position and low leverage, but persistent heavy losses, negative cash flow, and a demanding valuation mean it still needs to convert its high gross margin into operating profitability.
Price Behavior
Key Price Behavior Insights: • Breakout follow-through • Stretched rally • Support holding Support Level: $32.0-$32.8 Resistance Level: $33.2-$33.6 Over the last month, HTFL broke above resistance and surged to new highs, signaling strong bullish momentum but a stretched move that may need consolidation
Sentiment & News
Key News Insights: • Institutional stake • Software weakness • Portfolio repositioning Renewed institutional buying in HeartFlow signals fresh investor interest, while broader software कमजोरी and portfolio reshuffling point to mixed sentiment.
AI Summary
HTFL is transitioning from a “story stock” to a real scaling business with accelerating revenue, raised guidance, and strong gross margins, but the investment now hinges on whether management can convert that growth into operating leverage fast enough to justify a still-rich valuation amid persistent cash burn and patent/legal risk.
Description
HeartFlow offers a non-invasive diagnostic platform that converts a single coronary CT angiogram into a patient-specific 3D heart model and applies computational fluid dynamics and related analytics to quantify blood flow, arterial narrowing, and plaque characteristics. Founded in 2007 and based in Mountain View, California, the company distributes its technology globally to support clinical assessment and management of coronary artery disease.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Mar 23 | Mar 30 | HTFL | Heartflow, Inc. Common Stock | HeartFlow (HTFL) has multiple fresh growth catalysts—Aetna coverage expansion Jan 6, 2026, new clinical data at ACC and the launch/enrollment of the 5,000‑patient NAVIGATE‑PCI registry on March 16, 2026—and its stock has surged ~20–30% off the March low, positioning it as a high‑beta, event-driven healthcare IT momentum trade despite ongoing operating losses. | Closed | -11.0% |